Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

October 31, 2017

Study Completion Date

December 31, 2017

Conditions

Ovarian Cancer

Interventions

DRUG

OMP-54F28, Paclitaxel and Carboplatin

Trial Locations (4)

Memorial Sloan Kettering Cancer Center, New York

The University of Pennsylvania Health System, Philadelphia

Fox-Chase Cancer Center, Philadelphia

OU Medical Center Laboratory, Oklahoma City